,i #aadth ,,congress #ast ,session ,h4 ,r4 #bdch ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjae ,mr4 ,collins of ,new ,york introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to broader application of ,bayesian statistics and adaptive trial designs4 #a4 ,broader application of ,bayesian statistics and adaptive trial designs 7a7 ,proposals for use of innovative statistical methods in clinical protocols for drugs and biological products ,for purposes of assisting sponsors in incorporating adaptive trial design and ,bayesian methods into proposed clinical protocols and applications for new drugs under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 and biological products under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb71 the ,secretary shall conduct a public meeting and issue guidance in accordance with subsection 7b74 7b7 ,guidance addressing use of adaptive trial designs and ,bayesian methods 7#a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs 7in this subsection referred to as the ,secretary71 shall-- 7,a7 update and finalize the draft guidance addressing the use of adaptive trial design for drugs and biological products2 and 7,b7 issue draft guidance on the use of ,bayesian methods in the development and regulatory review and approval or licensure of drugs and biological products4 7#b7 ,contents ,the guidances under paragraph 7#a7 shall address-- 7,a7 the use of adaptive trial designs and ,bayesian methods in clinical trials1 including clinical trials proposed or submitted to help satisfy the substantial evidence standard under section #eje7;d7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;d772 7,b7 how sponsors may obtain feedback from the ,secretary on technical issues related to modeling and simulations prior to-- 7i7 completion of such modeling or simulations2 or 7ii7 the submission of resulting information to the ,secretary2 7,c7 the types of quantitative and qualitative information that should be submitted for review2 and 7,d7 recommended analysis methodologies4 7#c7 ,public meeting ,prior to updating or developing the guidances required by paragraph 7#a71 the ,secretary shall consult with stakeholders1 including representatives of regulated industry1 academia1 patient advocacy organizations1 and disease research foundations1 through a public meeting to be held not later than #a year after the date of enactment of this ,act4 7#d7 ,schedule ,the ,secretary shall publish-- 7,a7 the final guidance required by paragraph 7#a77;,a7 not later than #ah months after the date of the public meeting required by paragraph 7#c72 and 7,b7 the guidance required by paragraph 7#a77;,b7 not later than #dh months after the date of the public meeting required by paragraph 7#c74